| Terminated | CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or M Metastatic HER2 Positive Gastroesophageal Junction Cancer | Phase 1 / Phase 2 | 2022-04-14 |
| Withdrawn | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type Astrocytoma, Grade IV, Glioblastoma, Giant Cell Glioblastoma | Phase 1 / Phase 2 | 2022-03-08 |
| Terminated | Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme | Phase 1 | 2020-10-01 |
| Unknown | Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 | Phase 1 / Phase 2 | 2020-05-13 |
| Unknown | Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma Multiple Myeloma, Neoplasm, Plasma Cell, Neoplasms by Histologic Type | Phase 1 | 2020-05-12 |
| Terminated | Natural Killer Cell (CYNK-001) Infusions in Adults with AML Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute | Phase 1 | 2020-03-12 |
| Completed | A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or W Multiple Myeloma | Phase 1 | 2017-01-05 |
| Terminated | A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcu Leukemia, Myeloid, Acute | Phase 1 | 2016-07-11 |
| Completed | A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects W Diabetic Nephropathies, Peripheral Nervous System Diseases | Phase 2 | 2015-10-27 |
| Withdrawn | Safety, Hemodynamic Effects and Efficacy of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer Wit Diabetic Foot, Peripheral Arterial Disease | Phase 2 | 2015-06-01 |
| Terminated | Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Periphe Peripheral Arterial Disease, Diabetic Foot | Phase 2 | 2014-10-23 |
| Completed | Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD a Peripheral Arterial Disease, Diabetic Foot | Phase 1 | 2013-05-01 |
| Completed | A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of I Crohns Disease | Phase 1 | 2013-03-01 |
| Terminated | Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage Stage 2 Pulmonary Sarcoidosis, Stage 3 Pulmonary Sarcoidosis | Phase 1 | 2011-09-01 |
| Terminated | Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Isch Stroke, Acute, Middle Cerebral Artery Stroke, Posterior Cerebral Artery Stroke | Phase 2 | 2011-03-01 |
| Terminated | Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Acti Rheumatoid Arthritis | Phase 2 | 2010-12-01 |
| Completed | A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cel Crohn's Disease | Phase 2 | 2010-08-01 |